BVXP.L
Bioventix PLC
1W: +0.0%
1M: -10.8%
3M: -31.8%
YTD: -18.3%
1Y: -47.1%
3Y: -59.5%
5Y: -59.7%
£1,400.00 ($18.70)
-25.00 (-1.75%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
No convergence signal
Key Statistics
Market Cap£74.5M ($1.0M)
52W Range1350-3020
Volume12,044
Avg Volume7,552
Beta0.53
Dividend£150.00
Analyst Ratings
No analyst coverage
Company Info
CEOPeter John Harrison
Employees17
SectorHealthcare
IndustryBiotechnology
IPO Date2014-04-29
Websitebioventix.com
27–28 Eastcastle Street
Farnham W1W 8DH
GB
Farnham W1W 8DH
GB
441252728001
About Bioventix PLC
Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, infectious disease, oncology, and miscellaneous indications. It also provides contract SMAs and recombinant services. Bioventix PLC was incorporated in 2003 and is based in London, the United Kingdom.
Recent Insider Trades
No insider trades found